2018 AASM立场声明:医用大麻和阻塞性睡眠呼吸暂停的治疗

2018-03-30 美国睡眠医学会 J Clin Sleep Med. 2018;14(4):679–681.

2018年3月,美国睡眠医学会(AASM)发布了关于医用大麻和阻塞性睡眠呼吸暂停治疗的立场声明。成人阻塞性睡眠呼吸暂停(OSA)的诊断和有效治疗是当务之急。气道正压通气治疗仍然是治疗OSA最有效的方法。本文针对医用大麻和阻塞性睡眠呼吸暂停的治疗的相关内容提出相关立场声明,指出医用大麻和/或其合成提取物不应用于OSA的治疗。

中文标题:

2018 AASM立场声明:医用大麻和阻塞性睡眠呼吸暂停的治疗

英文标题:

Medical Cannabis and the Treatment of Obstructive Sleep Apnea: An American Academy of Sleep Medicine Position Statement

发布机构:

美国睡眠医学会

发布日期:

2018-03-30

简要介绍:

2018年3月,美国睡眠医学会(AASM)发布了关于医用大麻和阻塞性睡眠呼吸暂停治疗的立场声明。成人阻塞性睡眠呼吸暂停(OSA)的诊断和有效治疗是当务之急。气道正压通气治疗仍然是治疗OSA最有效的方法。本文针对医用大麻和阻塞性睡眠呼吸暂停的治疗的相关内容提出相关立场声明,指出医用大麻和/或其合成提取物不应用于OSA的治疗。

 

拓展指南:阻塞性睡眠呼吸暂停相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2018 AASM立场声明:医用大麻和阻塞性睡眠呼吸暂停的治疗)] GetToolGuiderByIdResponse(projectId=1, id=db1221c00158203c, title=2018 AASM立场声明:医用大麻和阻塞性睡眠呼吸暂停的治疗, enTitle=Medical Cannabis and the Treatment of Obstructive Sleep Apnea: An American Academy of Sleep Medicine Position Statement, guiderFrom=J Clin Sleep Med. 2018;14(4):679–681., authorId=null, author=, summary=2018年3月,美国睡眠医学会(AASM)发布了关于医用大麻和阻塞性睡眠呼吸暂停治疗的立场声明。成人阻塞性睡眠呼吸暂停(OSA)的诊断和有效治疗是当务之急。气道正压通气治疗仍然是治疗OSA最有效的方法。本文针对医用大麻和阻塞性睡眠呼吸暂停的治疗的相关内容提出相关立场声明,指出医用大麻和/或其合成提取物不应用于OSA的治疗。 , cover=, journalId=null, articlesId=null, associationId=38, associationName=美国睡眠医学会, associationIntro=美国睡眠医学会(AASM)学院设置睡眠医学保健,教育和出版实践参数,系统评价,临床指南及最佳实践指南的研究等领域的临床标准。每个指南是由独立的专家审查,所有文件至少每5年进行审查一次,并在必要时更新。, copyright=0, guiderPublishedTime=Fri Mar 30 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<P>2018年3月,美国睡眠医学会(AASM)发布了关于医用大麻和阻塞性睡眠呼吸暂停治疗的立场声明。成人阻塞性睡眠呼吸暂停(OSA)的诊断和有效治疗是当务之急。气道正压通气治疗仍然是治疗OSA最有效的方法。本文针对医用大麻和阻塞性睡眠呼吸暂停的治疗的相关内容提出相关立场声明,指出医用大麻和/或其合成提取物不应用于OSA的治疗。 </P> <P> </P>拓展指南:<strong>与<font color=red>阻塞性睡眠呼吸暂停</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=c02471c00152a3ed" title="2017 AASM意见书:应用家庭睡眠呼吸检测诊断儿童阻塞性睡眠呼吸暂停" target=_blank>2017 AASM意见书:应用家庭睡眠呼吸检测诊断儿童阻塞性睡眠呼吸暂停</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=808911c001ae88d7" title="2017 USPSTF建议声明:成人阻塞性睡眠呼吸暂停的筛查" target=_blank>2017 USPSTF建议声明:成人阻塞性睡眠呼吸暂停的筛查</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=e58191c001a6e819" title="2017 共识指南:阻塞性睡眠呼吸暂停减重手术围术期管理" target=_blank>2017 共识指南:阻塞性睡眠呼吸暂停减重手术围术期管理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=75b181c00139e253" title="2016 AASM临床实践指南:成人阻塞性睡眠呼吸暂停的诊断测试" target=_blank>2016 AASM临床实践指南:成人阻塞性睡眠呼吸暂停的诊断测试</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=c62891c001096853" title="2014 ACP临床实践指南:成人阻塞性睡眠呼吸暂停的诊断" target=_blank>2014 ACP临床实践指南:成人阻塞性睡眠呼吸暂停的诊断</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E9%98%BB%E5%A1%9E%E6%80%A7%E7%9D%A1%E7%9C%A0%E5%91%BC%E5%90%B8%E6%9A%82%E5%81%9C" target=_blank>有关阻塞性睡眠呼吸暂停更多指南</a></ul>, tagList=[TagDto(tagId=36552, tagName=医用大麻), TagDto(tagId=3180, tagName=阻塞性睡眠呼吸暂停)], categoryList=[CategoryDto(categoryId=12, categoryName=呼吸, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=0, guiderRegion=1, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4515, appHits=99, showAppHits=0, pcHits=3000, showPcHits=1739, likes=100, shares=0, comments=3, approvalStatus=1, publishedTime=Fri Apr 20 16:21:33 CST 2018, publishedTimeString=2018-03-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Fri Apr 20 16:21:33 CST 2018, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 10:03:24 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 AASM立场声明:医用大麻和阻塞性睡眠呼吸暂停的治疗)])
2018 AASM立场声明:医用大麻和阻塞性睡眠呼吸暂停的治疗
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1057126, encodeId=6bca105e126a8, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 15:55:59 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308245, encodeId=91d43082456a, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sun Apr 22 13:31:55 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307906, encodeId=12be30e90693, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Sat Apr 21 11:53:55 CST 2018, time=2018-04-21, status=1, ipAttribution=)]
    2021-10-03 H8888888

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1057126, encodeId=6bca105e126a8, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 15:55:59 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308245, encodeId=91d43082456a, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sun Apr 22 13:31:55 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307906, encodeId=12be30e90693, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Sat Apr 21 11:53:55 CST 2018, time=2018-04-21, status=1, ipAttribution=)]
    2018-04-22 131****1460

    学习了受益匪浅

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1057126, encodeId=6bca105e126a8, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 15:55:59 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308245, encodeId=91d43082456a, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sun Apr 22 13:31:55 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307906, encodeId=12be30e90693, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Sat Apr 21 11:53:55 CST 2018, time=2018-04-21, status=1, ipAttribution=)]
    2018-04-21 秀红

    学习了

    0